Nanoparticles and skin cancer

Gour, Vishal; Agrawal, Poornima; Pandey, Vikas; Kanwar, Indu Lata; Haider, Tanweer; Tiwari, Rahul; Soni, Vandana

doi:10.1016/b978-0-12-819793-6.00011-4

Cited by 6 publications

(6 citation statements)

References 171 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The stratum corneum (SC), the stratum lucidum, the stratum granulosum, the stratum spinosum, and the stratum germinatum are the different layers of the epidermis [24]. The SC and lucidum are non-vital layers made of lipids and corneocytes that act as a vital barrier against causing harm from radiation, stop the loss of body water, and block the entry of exogenous substances into the body [25]. Melanocytes are responsible for skin pigmentation, which later blocks harmful ultraviolet radiation [26].…”

Section: Introductionmentioning

confidence: 99%

“…The dermis primarily regulates the epidermis's body temperature, pressure, nutrition, and oxygen supply. The hypodermis, the skin's deepest layer, serves as an insulator, protects the body against shock, and stores energy in the form of fat [25].…”

Section: Introductionmentioning

confidence: 99%

“…One of the key contributors to the emergence of skin cancer is DNA damage. Ionizing radiation, biological therapy, the human papillomavirus (HPV), immunosuppression, and organ transplantation are additional risk factors [25,31]. Skin cancer can be treated using various conventional methods, such as surgery, cryotherapy, radiation, and photodynamic therapy (PDT), as well as more recent drug delivery technologies such as NPs, nanovesicles, nanoemulsions, and nanogels [32].…”

Section: Introductionmentioning

confidence: 99%

“…Skin cancer can be treated using various conventional methods, such as surgery, cryotherapy, radiation, and photodynamic therapy (PDT), as well as more recent drug delivery technologies such as NPs, nanovesicles, nanoemulsions, and nanogels [32]. There are many complications associated with conventional therapy, such as toxicity, inflammation, scarring, and poor patient compliance, which can be mitigated using novel nanotherapies [25]. As far as current knowledge, there are not commercially available nanosystems for the topical delivery of bioactive molecules for skin cancer.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Exploring Nanocarriers as Treatment Modalities for Skin Cancer

Adnan,

Akhter,

Afzal

et al. 2023

Molecules

View full text Add to dashboard Cite

Cancer is a progressive disease of multi-factorial origin that has risen worldwide, probably due to changes in lifestyle, food intake, and environmental changes as some of the reasons. Skin cancer can be classified into melanomas from melanocytes and nonmelanoma skin cancer (NMSC) from the epidermally-derived cell. Together it constitutes about 95% of skin cancer. Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) are creditworthy of 99% of NMSC due to the limited accessibility of conventional formulations in skin cancer cells of having multiple obstacles in treatment reply to this therapeutic regime. Despite this, it often encounters erratic bioavailability and absorption to the target. Nanoparticles developed through nanotechnology platforms could be the better topical skin cancer therapy option. To improve the topical delivery, the nano-sized delivery system is appropriate as it fuses with the cutaneous layer and fluidized membrane; thus, the deeper penetration of therapeutics could be possible to reach the target spot. This review briefly outlooks the various nanoparticle preparations, i.e., liposomes, niosomes, ethosomes, transferosomes, transethosomes, nanoemulsions, and nanoparticles technologies tested into skin cancer and impede their progress tend to concentrate in the skin layers. Nanocarriers have proved that they can considerably boost medication bioavailability, lowering the frequency of dosage and reducing the toxicity associated with high doses of the medication.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Exploring Nanocarriers as Treatment Modalities for Skin Cancer

Adnan,

Akhter,

Afzal

et al. 2023

Molecules

View full text Add to dashboard Cite

show abstract

“…Further, improvement of the treatment options is desired in order to effectively treat tumors with a minimum of side effects [ 6 , 7 , 8 ]. In this respect, the nanocarrier-based platforms, with tunable properties, have the ability to enhance the biodistribution and to deliver the anti-cancer drugs into tumors in a targeted way and to leave the healthy cells unaffected [ 7 , 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Anti-Melanoma Activity of L-Cysteine-Coated Iron Oxide Nanoparticles Loaded with Doxorubicin

et al. 2023

View full text Add to dashboard Cite

In this study, we report on the synthesis of L-Cysteine (L-Cys)-coated magnetic iron oxide nanoparticles (NPs) loaded with doxorubicin (Dox). The Fe3O4-L-Cys-Dox NPs were extensively characterized for their compositional and morpho-structural features using EDS, SAED, XRD, FTIR and TEM. XPS, Mӧssbauer spectroscopy and SQUID measurements were also performed to determine the electronic and magnetic properties of the Fe3O4-L-Cys-Dox nanoparticles. Moreover, by means of a FO-SPR sensor, we evidenced and confirmed the binding of Dox to L-Cys. Biological tests on mouse (B16F10) and human (A375) metastatic melanoma cells evidenced the internalization of magnetic nanoparticles delivering Dox. Half maximum inhibitory concentration IC50 values of Fe3O4-L-Cys-Dox were determined for both cell lines: 4.26 µg/mL for A375 and 2.74 µg/mL for B16F10, as compared to 60.74 and 98.75 µg/mL, respectively, for unloaded controls. Incubation of cells with Fe3O4-L-Cys-Dox modulated MAPK signaling pathway activity 3 h post-treatment and produced cell cycle arrest and increased apoptosis by 48 h. We show that within the first 2 h of incubation in physiological (pH = 7.4) media, ~10–15 µM Dox/h was released from a 200 µg/mL Fe3O4-L-Cys-Dox solution, as compared to double upon incubation in citrate solution (pH = 3), which resembles acidic environment conditions. Our results highlight the potential of Fe3O4-L-Cys-Dox NPs as efficient drug delivery vehicles in melanoma therapy.

show abstract